- Trials with a EudraCT protocol (138)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
138 result(s) found for: Z drugs.
Displaying page 1 of 7.
EudraCT Number: 2017-000994-35 | Sponsor Protocol Number: 06032017 | Start Date*: 2018-08-02 | |||||||||||
Sponsor Name:Hospital General Universitario de Alicante | |||||||||||||
Full Title: Study of tolerability of iron liposome compared to ferrous sulphate in pregnant women with iron deficiency anemia. | |||||||||||||
Medical condition: Iron deficiency anaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000735-14 | Sponsor Protocol Number: L-A/2017/COM/01 | Start Date*: 2018-01-19 |
Sponsor Name:Lek-Am Sp. z o.o. | ||
Full Title: The efficacy and safety of new formulation of combination of fluticasone propionate / salmeterol (125μg / 25μg) in MDI HFA inhaler compared with the reference drug at a dose of 500μg / 50μg in DPI... | ||
Medical condition: Asthma is a common, chronic respiratory disease affecting 1–18% of the population in different countries. Asthma is characterized by variable symptoms of wheeze, shortness of breath, chest tightnes... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: PL (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-001552-19 | Sponsor Protocol Number: TOPMATEPY4067 | Start Date*: 2014-12-16 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Randomized, Active-Controlled, Open-Label, Flexible-Dose Study to Assess the Safety and Tolerability of Topiramate as Monotherapy Compared with Levetiracetam as Monotherapy in Pediatric Subjects ... | |||||||||||||
Medical condition: New-onset or recent-onset epilepsy. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) IT (Completed) HU (Completed) BE (Completed) DE (Completed) GB (Completed) FR (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000323-43 | Sponsor Protocol Number: D6020C00001 | Start Date*: 2017-10-31 | |||||||||||
Sponsor Name:MedImmune, LLC, a wholly-owned subsidiary of AstraZeneca PLC | |||||||||||||
Full Title: A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination with Durvalumab versus Nivolumab Monotherapy in Subjects with Select Advanced Malign... | |||||||||||||
Medical condition: clear-cell renal cell carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000037-51 | Sponsor Protocol Number: CA204-185 | Start Date*: 2020-06-22 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab | |||||||||||||
Medical condition: Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) BE (Completed) ES (Ongoing) PL (Completed) HU (Completed) IT (Completed) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004827-29 | Sponsor Protocol Number: VX14-661-110 | Start Date*: 2015-09-01 | |||||||||||
Sponsor Name:Vertex Pharmaceuticals Incorporated | |||||||||||||
Full Title: A Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long term Treatment With VX 661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, ... | |||||||||||||
Medical condition: Cystic Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) IE (Completed) GB (GB - no longer in EU/EEA) BE (Completed) SE (Completed) AT (Completed) FR (Completed) DK (Completed) NL (Completed) DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000543-16 | Sponsor Protocol Number: VX14-809-109 | Start Date*: 2015-06-19 |
Sponsor Name:Vertex Pharmaceuticals Incorporated | ||
Full Title: A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fib... | ||
Medical condition: Cystic Fibrosis | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Completed) DE (Completed) SE (Completed) DK (Completed) BE (Completed) FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-001462-81 | Sponsor Protocol Number: FARM7KP2PX | Start Date*: 2008-10-27 | |||||||||||
Sponsor Name:OSPEDALE POLICLINICO S. MATTEO | |||||||||||||
Full Title: Effects of Losartan versus Nebivolol versus the association of both on the progression of aortic root dilation in Marfan Syndrome (MFS) with FBN1 gene mutations | |||||||||||||
Medical condition: Marfan Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000577-13 | Sponsor Protocol Number: kajakbe191086 | Start Date*: 2015-09-09 |
Sponsor Name:Oslo University Hospital | ||
Full Title: Therapeutic effects of BNP in uncontrolled hypertensive patients 1 | ||
Medical condition: Uncontrolled hypertension (UHT, i.e. blood pressure ≥ 150/90, or ≥ 150/85 mm Hg in diabetic patients) despite treatment with at least two different classes of antihypertensive medications. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2017-000641-44 | Sponsor Protocol Number: TailorDose-II | Start Date*: 2017-04-28 | |||||||||||
Sponsor Name:Karolinska intitutet | |||||||||||||
Full Title: TailorDose®-II: Therapeutic dose monitoring of commonly used cytostatic drugs/regimes indicated for breast cancer | |||||||||||||
Medical condition: Newly diagnosed pre- or post-operative breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-005142-12 | Sponsor Protocol Number: TMC207-C203 | Start Date*: 2005-06-25 |
Sponsor Name:Tibotec Pharmaceuticals Limited | ||
Full Title: An open-label study to evaluate the extended early bactericidal activity, safety, tolerability and pharmacokinetics of multiple doses (m.d.) of TMC207 oral solution (os) and isoniazid (JH), m.d. of... | ||
Medical condition: Tuberculosis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-001503-26 | Sponsor Protocol Number: FER-CARS-03 | Start Date*: 2008-10-17 | ||||||||||||||||
Sponsor Name:Vifor Pharma - Vifor (International) AG | ||||||||||||||||||
Full Title: EFfect of Ferric Carboxymaltose on exercIse CApacity and Cardiac function in patients with iron deficiencY and chronic Heart Failure (EFFICACY-HF) | ||||||||||||||||||
Medical condition: Ambulatory patients with stable symptomatic chronic CHF (congestive heart failure) and iron deficiency. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Prematurely Ended) DE (Completed) NL (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-000469-62 | Sponsor Protocol Number: 2017-000469-62 | Start Date*: 2017-07-24 | ||||||||||||||||
Sponsor Name:Fundació Clínic per a la Recerca Biomèdica | ||||||||||||||||||
Full Title: Pilot single‐arm clinical trial to evaluate the efficacy, PK interactions and safety of dolutegravir plus 2 NRTIs in HIV‐1‐infected solid organ transplant patients | ||||||||||||||||||
Medical condition: HIV-1 infected solid organ transplant patients | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001078-41 | Sponsor Protocol Number: VX13-809-011 | Start Date*: 2017-03-27 | |||||||||||
Sponsor Name: Vertex Pharmaceuticals Incorporated | |||||||||||||
Full Title: A Phase 3, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozy... | |||||||||||||
Medical condition: Cystic Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005052-37 | Sponsor Protocol Number: BRAVO | Start Date*: 2021-04-01 | ||||||||||||||||||||||||||
Sponsor Name:Institute of Mother and Child | ||||||||||||||||||||||||||||
Full Title: Optymalizacja czasu leczenia i dawkowania wemurafenibu u małoletnich pacjentów z opornymi na konwencjonalną terapię rozrostami z komórek histiocytarnych z obecnością mutacji w genie BRAF. | ||||||||||||||||||||||||||||
Medical condition: histiocytic cell proliferation | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: PL (Trial now transitioned) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016728-29 | Sponsor Protocol Number: P-Monofer-CKD-02 | Start Date*: 2010-02-03 | ||||||||||||||||
Sponsor Name:Pharmacosmos A/S | ||||||||||||||||||
Full Title: A Phase III, randomized, comparative, open-label study of intravenous Iron Isomaltoside 1000 (Monofer®) administered by infusions or repeated bolus injections in comparison with oral Iron Sulphate ... | ||||||||||||||||||
Medical condition: Non-dialysis dependent chronic kidney disease and with renal-related anaemia (NDD-CKD) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Completed) DK (Completed) GB (Completed) IE (Completed) DE (Completed) PL (Completed) AT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-016727-53 | Sponsor Protocol Number: P-Monofer-CIA-01 | Start Date*: 2010-04-12 | |||||||||||
Sponsor Name:Pharmacosmos A/S | |||||||||||||
Full Title: A phase III, randomized, open-label study of intravenous iron isomaltoside 1000 (Monofer®) as mono therapy (without erythropoeisis stimulating agents) in comparison with oral iron sulfate in subjec... | |||||||||||||
Medical condition: non-myeloid malignancies associated with chemotherapy induced anaemia (CIA). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) GB (Completed) SE (Completed) DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011774-15 | Sponsor Protocol Number: BASt01 | Start Date*: 2009-07-15 | |||||||||||||||||||||
Sponsor Name:Federal Highway Research Institute / Bundesanstalt für Straßenwesen (BASt) | |||||||||||||||||||||||
Full Title: Effects of opioid analgesics on driving ability of pain patients [Untersuchung zur Fahrsicherheit von Schmerzpatienten] | |||||||||||||||||||||||
Medical condition: patients suffering from chronic non-cancer pain responsive to opioid analgesics under already existing long-term treatment | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) NL (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-000333-13 | Sponsor Protocol Number: APHP200046 | Start Date*: Information not available in EudraCT |
Sponsor Name:APHP DRCI | ||
Full Title: Efficacy of the nonavalent HPV vaccine in the treatment of difficult-to-treat palmo-plantar warts | ||
Medical condition: Vaccination by nonavalent vaccine against HPV could lead to a complete resolution of difficult-to-treat palmo-plantar warts in patients of more than 15 years and 3 months of age | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2021-005383-22 | Sponsor Protocol Number: Kognition | Start Date*: 2022-07-27 |
Sponsor Name:Universitätsmedizin Göttingen | ||
Full Title: Cognitive Function, Depression, Anxiety, and Quality of Life in Chronic Heart Failure Patients with Iron Deficiency with and without Anaemia: Effects of Intravenous Iron (Ferric Derisomaltose) | ||
Medical condition: Iron deficiency in patients with chronic heart failure and mild cognitive impairment | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Trial now transitioned) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
